Alizyme completes Phase IIb obesity trial enrollment

Alizyme (LSE:AZM) completed enrollment of 370 clinically obese patients in a double-blind, placebo-controlled, European Phase IIb trial of ATL-962, a gastrointestinal lipase inhibitor. The trial will ...